Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

22articles mentioning diseases

80disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: DcSSc ×

DcSSc

This disease is selected. Its supporting articles are shown below.

Articles mentioning DcSSc

22 articles · page 2 of 2

OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial

jsrd · abstract · 2026-06-05 · 2 matching annotations

79.5%

severe refractory SSc dcSSc SSc-ILD BMS-986353 nintedanib NCT05869955

…Introduction In severe refractory SSc, treatments that halt disease progression and improve long-term…

P.208 Rethinking skin assessment: analysis of individual rodnan skin sites scores in early diffuse systemic sclerosis using the EUSTAR cohort

jsrd · abstract · 2026-06-05 · 2 matching annotations

89.0%

systemic sclerosis (SSc)dcSSc EUSTAR

…e used in clinical practice and research for skin assessment in systemic sclerosis (SSc). However, this score has important limitations, including its h…

OC.54 Timing matters: early autologous stem cel transplantation shows a lower mortality in high-risk diffuse cutaneous systemic sclerosis – preliminary results from the upside trial

jsrd · abstract · 2026-06-05 · 1 matching annotations

75.9%

Diffuse cutaneous systemic sclerosis (dcSSc)dcSSc Health Assessment Questionnaire mycophenolate mofetil cyclophosphamide immunosuppressants CYC ATG

…Introduction Diffuse cutaneous systemic sclerosis (dcSSc) carries high morbidity and mortality. Several treatments aim to…

P.151 Peri-myocarditis leading to cardiac tamponade in systemic sclerosis overlap

jsrd · abstract · 2026-06-05 · 1 matching annotations

84.3%

systemic sclerosis dcSSc myositis Rituximab Prednisolone mycophenolate mofetil cyclophosphamide

…sion-making. Herein, we report a rare case of diffuse cutaneous systemic sclerosis (dcSSc) overlapping necrotizing autoimmune myopathy (NAM) with …

P.164 Evaluating gastrointestinal involvement in systemic sclerosis using the GIT 2.0 instrument and the impact of immunosuppressive therapy in a Chinese cohort

jsrd · abstract · 2026-06-05 · 1 matching annotations

82.2%

systemic sclerosis (SSc)myositis dcSSc SSc scleroderma renal crisis ILD mycophenolate mofetil tofacitinib tocilizumab rituximab+1 more

…volvement is a common and serious complication in patients with systemic sclerosis (SSc), often leading to poor prognosis and posing ongoing challenges …

P.245 Serum type I interferon activity as a biomarker of morbimortality in systemic sclerosis independent of cutaneous subset

jsrd · abstract · 2026-06-05 · 1 matching annotations

78.2%

systemic sclerosis (SSc)dcSSc SSc Myriad RBM CCL2 CCL8 CCL19 EudraCT targeted therapies

… CCL19, CXCL9, CXCL10, and CXCL11 (Myriad RBM) in patients with systemic sclerosis (SSc) fulfilling the 2013 ACR/EULAR classification criteria, who were…

P.249 Efficacy of autologous hematopoietic stem cell transplantation in diffuse cutaneous systemic sclerosis: a case series linking outcomes to patient age and conditioning regimen

jsrd · abstract · 2026-06-05 · 1 matching annotations

75.8%

Diffuse cutaneous systemic sclerosis (dcSSc)dcSSc mycophenolate mofetil methotrexate cyclophosphamide rituximab fludarabine anti-thymocyte globulin

…Introduction Diffuse cutaneous systemic sclerosis (dcSSc) is a severe autoimmune disease characterized by progressive ski…

P.253 Unveiling the storm: prevalence and risk factors for cytokine release syndrome in systemic sclerosis patients undergoing autologous hematopoietic stem cell transplantation

jsrd · abstract · 2026-06-05 · 1 matching annotations

80.2%

dcSSc cytokine release syndrome (CRS)diffuse cutaneous systemic sclerosis (dcSSc)CRS tocilizumab eculizumab ATG Dutch university hospitals American Society for Transplantation and Cellular Therapy

…the median disease duration was 13 months (IQR 7-23). 87.1% had dcSSc and 12.9% had limited cutaneous SSc. At baseline the mean perce…

P.268 Efficacy and safety results from a phase 2B trial of fipaxalparant in patients with diffuse cutaneous systemic sclerosis

jsrd · abstract · 2026-06-05 · 1 matching annotations

78.8%

Diffuse cutaneous systemic sclerosis (dcSSc)dcSSc fipaxalparant Health Assessment Questionnaire

…Introduction Diffuse cutaneous systemic sclerosis (dcSSc) is a rare autoimmune disease with skin and internal organ fibro…

P.357 Risk factors for cancer in systemic sclerosis, impact on disease phenotype and prognosis, and exploration of machine learning algorithms for personalized screening strategies: an EUSTAR study

jsrd · abstract · 2026-06-05 · 1 matching annotations

80.0%

…) and negatively with digital ulcers (OR 0.4; CI 0.2-0.7). Lung cancer was associated with disease duration (OR 1.04; CI 1-1.08), smok…